Jasper Bolsters Pipeline with Kira Acquisition and $132 Million Private Placement
Combined company advances KP-104 and briquilimab with cash runway through H2 2028.
/ 2 items
Combined company advances KP-104 and briquilimab with cash runway through H2 2028.
Jasper Therapeutics (JSPR) shares rise 60% after experimental drug briquilimab shows promising results in early-stage asthma study, improving lung function and reducing inflammation.